Browse the evidence

Body mass index is associated with all-cause and cardiovascular disease mortality in both men and women.

BMI should be considered a critical factor in assessing mortality risk.

TGD patients frequently present to their endocrinologists for individualized, gender-affirming support to meet BMI cutoffs for GAS.

Endocrinologists should provide tailored support to help TGD patients achieve necessary BMI for GAS.

Multidisciplinary management considerations are offered for clinicians to assist TGD patients with obesity navigate BMI requirements to access GAS.

Clinicians should adopt a multidisciplinary approach to support TGD patients in meeting BMI requirements for GAS.

Low-carbohydrate diets may not be any better than other popular diets in helping people keep weight off permanently.

Consider a variety of diet options for long-term weight maintenance.

Static stretching did not significantly interfere with total number of repetitions or total volume of exercise.

Static stretching may not negatively impact overall strength-endurance performance metrics.

Cognitive outcome is not a limitation for the use of calorie restriction for health improvement.

Health practitioners can recommend CR without fear of adverse cognitive effects.

Obesity is accompanied by significant health consequences, including increased incidence of heart disease, some types of cancers, and Type 2 diabetes.

Healthcare providers should consider these health risks when addressing obesity.

The marketing of sugar-sweetened beverages may contribute to global trends in calorie intake and obesity.

Marketers and public health officials should consider the impact of beverage marketing on obesity trends.

Menstrual frequency increased in all groups from baseline to 12 months.

This suggests that while HIT may not be effective, some improvement in menstrual frequency can occur over time.

Semaglutide demonstrated an SAE incidence of 8.9%, compared to 6.2% for Liraglutide.

Practitioners should be aware of the SAE incidence when prescribing these medications.

Discontinuation rates due to adverse effects were 10.3% for Semaglutide and 8.3% for Liraglutide.

Practitioners should consider these discontinuation rates when evaluating treatment options.

GLP-1a therapy was associated with a mean change in body mass index (BMI) of −0.83 kg/m2 in treated patients compared to −0.70 kg/m2 in those without GLP-1a therapy.

GLP-1a therapy may lead to modest reductions in BMI in a real-world setting.

In clinical practice, GLP-1a therapy was associated with more modest reductions in weight and HbA1c than shown in prior RCTs.

Practitioners should be aware that real-world outcomes may differ from clinical trial results.

81.5% of patients achieved excess weight loss (EWL) ≥50% and 51.1% achieved EWL ≥70% during follow-up.

Surgeons can expect a significant proportion of patients to achieve substantial weight loss post-surgery.

Laparoscopic Roux-en-Y gastric bypass (LRYGB) results in higher rates of sustained excess weight loss compared to laparoscopic sleeve gastrectomy (LSG).

LRYGB may be a more effective option for patients seeking long-term weight loss.

A greater proportion of AOM-naïve patients achieved ≥15% and ≥20% total body weight loss at 12 months compared to non-AOM-naïve patients.

Clinicians should note that AOM-naïve patients are more likely to achieve significant weight loss with semaglutide.

Obesity is a major public health problem with a prevalence increasing at an alarming rate worldwide.

Health practitioners should prioritize addressing obesity as a critical public health issue.

The effectiveness of currently approved anti-obesity drugs and other therapeutic avenues is reviewed.

Healthcare providers should stay informed about the effectiveness of anti-obesity medications.

Several agencies have approved tirzepatide for the treatment of type 2 diabetes and obesity.

Tirzepatide is a viable treatment option that is recognized by regulatory agencies for managing type 2 diabetes and obesity.

Brown adipose tissue (BAT) is identified as a thermogenic organ in human adults, which may be targeted for obesity and cardiometabolic disease treatment.

Activating BAT could be a novel strategy for treating obesity and related diseases.

Integrating shared decision-making (SDM) into obesity management enhances patient-centered care and has the potential to improve long-term outcomes.

Practitioners should consider incorporating SDM to enhance patient engagement and outcomes in obesity care.

Programs incorporating SDM reported improved patient engagement, satisfaction, and health outcomes across diverse demographic groups.

Incorporating SDM can lead to better patient experiences and outcomes in obesity management.

Common facilitators of SDM success include the use of decision aids, culturally tailored counseling, and multidisciplinary team involvement.

Healthcare providers should utilize decision aids and culturally tailored approaches to enhance SDM in obesity care.

Total daily calorie intake measured by the questionnaire correlated with formal dietary review.

The questionnaire can provide a reliable estimate of calorie intake for dietary assessments.